Introduction ▼
Adrenal insufficiency (AI) results from many diseases, which impact on hypothalamic-pituitaryadrenal axis function, resulting in partial or complete deficiency of adrenal steroid production. These are usually divided into adrenal causes [primary adrenal insufficiency (PAI) including Addison's disease (AD)] and secondary adrenal insufficiency (SAI), due to failure of adrenocorticotropin (ACTH) secretion resulting from disease or injury to the pituitary gland or hypothalamus, and due to the consequences of exposure to corticosteroid pharmacotherapy (iatrogenic AI). The estimated prevalence of Addison's disease (AD) or PAI varies between 90 and 140 per million in Western countries [1] [2] [3] [4] [5] and, although the incidence and prevalence of PAI in Australia is unknown, it is assumed that there are approximately 100 prevalent cases per million.
Morbidity from adrenal insufficiency (AI) in Australia is poorly described. The objective of this study was to evaluate AI morbidity patterns in adults between 1999/2000 and 2011/2012 using national databases. A descriptive study of hospitalisations for AI and adrenal crises (AC) in adults and trends in prescriptions for 2 short-acting glucocorticoids (GC) was designed. The setting was the Australian healthcare system. Main outcome measures are the trends in hospitalisation and prescription rates. There were 7 378 hospital admissions for treatment of AI in adults between 1999/00 and 2011/12. Of these, 29.5 % were for an AC. Admission rates for AC increased from 9.5 to 12.4 admissions/10 6 /year (p < 0.05). There was a 5.8 % decrease in admission rates for AI (excluding AC), from 27.0 to 25.5/10 6 /year (p = ns). Short-acting GC [hydrocortisone (HCT) and cortisone acetate (CA)] prescription rates increased significantly (p < 0.001) from 3 176.1/10 6 to 3 463.8/10 6 . Prescription rates for CA decreased by 22.4 % (p < 0.001) but HCT prescription rates increased to 77.1 % (p < 0.001). The increase in AC admission rates was positively correlated with the rise in both the total GC prescription rate (r = 0.63, p < 0.05) and the HCT prescription rate (r = 0.74, p < 0.01). Over the 13-year study period, there was a 30.8 % increase in hospitalisation rates for ACs and a concomitant 77.1 % increase in prescribing of HCT. The association between AC events and HCT use and/or reduced effective GC dose is plausibly causal, but confirmatory studies are required before suggesting any change to GC replacement in AI.
Endocrine Care
(HCT) (biological activity 8 h) or a longer acting GC such as prednisolone/prednisone or dexamethasone (biological activity 13-16 and 36-54 h respectively) and mineralocorticoid replacement therapy is also used in the majority of patients with PAI. Modern recommended daily dosing of GCs is 30-50 % lower than previously favoured, following data revealing that endogenous cortisol production rates are lower than earlier estimates at 9.9 ± 2.7 mg/day [13] . HCT is generally recommended in reviews, given that long-acting GCs have been associated retrospectively with evidence of mild Cushingoid effects [14] and increased risks of osteoporosis and metabolic problems such as hyperlipidaemia [15] [16] [17] , and HCT does not require physiological activation, while CA does. Divided daily dosing is also recommended in an effort to more closely mimic the circadian rhythm [18, 19] , although there are data to suggest that this approach compromises compliance [20] . In addition, cortisol levels are highly variable between individuals taking any of the current HCT schedules [21] . Currently a HCT dose based on 10-12 mg/m 2 body surface area, or approximately 15-24 mg daily for adults, in 2 or 3 doses per day is recommended [22] . However, it is possible that finely adjusted HCT will leave some patients transiently deficient of cortisol due to highly variable pharmacokinetics and brief tissue bioactivity. Should these deficient episodes coincide with periods of stress and increased cortisol requirement, an adrenal crisis may eventuate [10] . In the present study, we aimed to examine patterns of hospitalisation and use of selected adrenal steroid replacement therapies in AI patients in Australia using available data sources over a 13-year period. Information on the Australian population is available from the Australian Bureau of Statistics (ABS), which publishes data on the population in each census year, and the inter-censal estimates for the intervening years. We extracted population data on each year included in the study by 5-year age groups and sex. These groups were combined to give the denominator populations for each year of the study. Data on all pharmaceuticals supplied through the Australian Pharmaceutical Benefits Scheme (PBS) are available from the PBS by financial year and pharmaceutical formulation. We extracted data on all prescriptions for 2 GCs: HCT (4 mg and 20 mg); and CA (5 mg and 25 mg). Prescriptions for prednisolone/ prednisone and dexamethasone were not included, as these formulations are not exclusively prescribed for AI. We also extracted data on prescriptions for the mineralocorticoid, fludrocortisone acetate (FA) (0.1 mg), which is used primarily for PAI. Trends in prescriptions of the selected steroid replacement therapies were analysed for each year of the study period, from 1999/2000 to 2011/12. Statistical analysis was conducted using the Microsoft Excel (2007, Redmond, Washington: Microsoft) and SPSS-X (IBM SPSS Statistics for Windows, Version 20.0 Armonk, NY: IBM Corp) software packages. To adjust for changes in the underlying prevalence of AI, secondary to changes in the Australian population, admission rates per million population were calculated by dividing the number of admissions for each year by the corresponding population and converting this into a rate per 10 6 population. Prescription rates were calculated in the same way. A z-score for the difference in 2 proportions was used to assess the significance of the observed difference between the admission and prescription rates between the last year of the study and the base year. Pearson correlation coefficients were calculated to assess the association between admission and the prescription rates. A significance level of p < 0.05 was used throughout the analysis.
Materials and Methods

Results
▼
Hospital Admissions
Over the study period, there were a total of 7 378 admissions in adults aged 20 years and over recorded for all causes of AI. The annual number of admissions increased by 38.3 %, from 465 in 1999/00 to 643 admissions in 2011/12. This corresponded to a 3.7 % increase in admission rates from 36.6 to 37.9/10 6 population/year, which was not significant. The changes in the total number of admissions and the number of admissions by AI category are shown in • ▶ Table 1 . Fig. 2) .
Of the 2 GCs considered in this study, CA was prescribed more frequently than HCT for the majority of the study period ( • ▶ Fig. 2) and the total number of prescriptions for CA increased slightly (3.5 %) from 27 635 to 28 594 prescriptions over this time. However, after adjusting for the increases in the population, the pre- Fig. 2) .
By comparison, there was a very substantial increase (136.1 %) in the total number of HCT prescriptions from 12 764 in 1999/2000 to 30 136 prescriptions in 2011/12. The corresponding rates were 1 003.5/10 6 /year and 1 777.4/10 6 /year respectively, representing a significant (z = − 54.9, p < 0.001) increase of 77.1 %, after adjustment for population increases ( • ▶ Fig. 2) .
In addition, there was a considerable increase (87. 
Hospital admissions and pharmaceutical prescriptions
The increase in AC admission rates over the study period was positively correlated with the observed rise in the combined GC prescription rate (r = 0.63, p < 0.05) ( • ▶ Fig. 3) . The AC admission rates were also positively correlated with the HCT prescription rates (r = 0.74, p < 0.01) but were negatively correlated ( − 0.71, p < 0.01) with the change in CA prescription rates and were not significantly correlated with the change in FA prescription rates. By comparison, the change in the AI (non-AC) admission rate was not significantly correlated with the change in the total GC, HCT, CA, or FA prescription rates.
Discussion
▼
The results of this investigation provide some new insights into the epidemiology and utilisation of health services by adult patients with hypoadrenalism in Australia. The present study demonstrated that, while there was a small increase (3.7 %) in the admission rates for all causes of AI over the study period, this was comprised of a 5.8 % reduction in admission rates for AI (excluding AC) and a substantial (30.8 %) increase in admission rates for an AC. Within the category of AI (excluding AC) there was a reduction in admission rates for both PAI and hypopituitarism (36.1 and 44.1 %, respectively). The remaining admissions consisted of an increasing number of patients classified as having "other causes and unspecified causes of hypoadrenalism" and a small number of patients with "drug induced hypoadrenalism". The reasons for the changing pattern of admissions for AC relative to AI are unclear but they may be due to changes in the presentation of AI to the more life threatening AC, which is characterised by hypotension and electrolyte disturbances. Disturbingly, the increased rates of admission for AC (but not the rates of AI excluding AC) were significantly correlated with the increased prescription rates of both GCs combined, in addition to the prescription rates of the short-acting GC hydrocortisone, during a time when the use of lower dose, short-acting GCs was recommended. Specific programs to increase clinician's awareness of AI, and AC in particular, have not been conducted in Australia and for this reason it is unlikely that an increased understanding of AI, which could be reflected in a greater likelihood to diagnose symptomatic AI as an AC, would account for the changes in AC incidence that were observed in this study. Irrespective of the type of GC replacement therapy, the mainstays of AC prevention involve the use of stress doses with illness, parenteral glucocorticoids (GC) and hospitalisation when required, and a MedicAlert or similar identification to indicate steroid dependence to medical attendants [22] . Although AI is rare in Australia, the results of the present study indicate that there is a disproportionate utilisation of hospital services by these patients. In 2011/12, there were 126.4 admissions for a principal diagnosis of AI per 1 000 presumed cases, corresponding to more than 10 % of this estimated total caseload. This suggests that a proportion of patients required hospital admission for management of symptomatic AI, either due to problems with stress management or due to underlying problems with intercurrent illness. There are a number of factors such as co-morbidities [12, 24, 25] and a predisposition to complications such as bacterial infections [25] [26] [27] , which may result in patients with AI requiring greater levels of hospital care. In addition, a number of studies have shown that some patients with AI have difficulties managing their disease during times of illness and injury, necessitating hospital care for patients who may have been able to be managed successfully at home [10, 28] . The incidence and prevalence of AI in Australia are unknown but we are unaware of any evidence suggesting a change in the incidence of AI in this country, which might explain the rise in AC rates. It is assumed that Australia has similar prevalence rates to those estimated for the US [29] and the UK [3] , as populations in Scandinavia and Northern Europe [5, 30] have a greater propensity to autoimmune disease than other groups. In addition, some published prevalence estimates include patients whose AD is a result of tuberculous adrenal failure [3] , which is not a feature of the current Australian experience. Further, while HIV infection may play an increasing role in the aetiology of AD in some countries, this is unlikely to feature as part of the Australian AD population [31] . Autoimmune disease is considered to be the main aetiological factor in the development of AD in Australia, as it is in a number of other countries [5, 29, 30, 32] and, as autoimmune disease is more common in women than men, it is assumed that women are more often affected by AD [33] . In this study, we found that men represented approximately 40 % of the total patient admissions, a higher proportion than was expected but consistent with the male/female ratio seen in a Swedish study [33] . We observed significant increases in prescription rates for GCs and FA over the study, which may suggest that the background prevalence of AD is greater than the 100/million population that is accepted as the most likely estimate of prevalence in Australia. However, it is likely that the observed increase in the prescription rates for FA may be unrelated to changes in the background prevalence of AD in the population, as this change may be a reflection of the increasing use of this formulation in the treatment of postural hypotension, especially in the elderly [34] .
With the exception of the last year of the study, in which the number of prescriptions for HCT exceeded those for CA for the first time (28 594 prescriptions in 2011/12 compared to 30 136 for hydrocortisone), CA was the more frequently prescribed GC, although the rate declined 22.4 % over the duration of the study. By comparison, the substantial increase (77.1 %) in the HCT prescription rate, most probably reflected clinicians' responses to the recommendation that HCT is the preferred GC to manage adrenal failure [22] . CA has been available since shortly after its isolation and initial clinical use in 1948, with HCT and synthetic GCs becoming available more recently. The reason for the comparatively high rate of CA prescribing is, therefore, uncertain. Patient compliance and preferences may play some role in explaining this apparent anomaly, as HCT is usually recommended in at least 2 but often 3 doses per day which, although accepted by patients in clinical trials, may not be an acceptable regimen for some patients or may reduce medication adherence [19, 20] . In this analysis, we used data from 2 national administrative datasets. These data provide a wealth of information on aspects of utilisation of health services, including trends over time but they have some limitations. Hospitalisation data provide some information on episodes of care, including the principal diagnosis of the patient, but they are not able to identify the hospital utilisation of individual patients and, therefore, cannot differentiate multiple admissions for the same individual vs. single admissions for different individuals. In addition, there may be inaccuracies in coding and it is possible that some cases of AC, for example, may be coded as other problems that may have precipitated the crisis such as infections or gastroenteritis. There may also be some variability among clinicians with regards to the diagnostic criteria for classification of an AC, as opposed to symptomatic AI. Further, these data cannot include information on patients who have a fatal AC outside the hospital setting and while these can occur, national mortality statistics for deaths due to adrenal diseases have not changed over recent years. Similarly, pharmaceutical prescription data do not enable the identification of individual treatment histories and do not include patient diagnosis, so we were unable to differentiate prescriptions for PAI from secondary (pituitary) causes or FA prescriptions to treat postural hypotension from those used to treat AI. Nor do these prescription data enable the estimation of dose, administration regimen, or the relationship between treatment type and AC as they are only made available in aggregate the form. However, we believe that these issues are important and that further research may be warranted. Over 13 years, there has been a marked increase in the rates of ACs, a life-threatening problem that has been estimated in some studies to have an annual risk in AD of between 6 to 10 % [11] . Increased HCT prescribing in Australia corresponded with a period where HCT and, to a lesser extent the similar short acting GC, CA, have been advocated in lower doses in AI. Although we were not able to examine doses of GC used or determine that all of the increased HCT prescribing relates to AI, we suggest that there may be an association between AC events and the increasing use of HCT, probably given in lower doses than in the past. This association is plausible but requires further validation and detailed investigation prior to altering treatment guidelines.
